US6063396A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods and compositions for the modulation of cell proliferation and wound healing
Assignee: Houston Biotechnology Inc
•
Filing: 1996-02-12
•
Granted: 2000-05-16
•
Expires: 2016-02-12
Abstract
Abstract Implants which are capable of sustained release of a cell proliferation modulating agent, together with methods for their preparation and use, are provided. The proliferation modulating agent is associated either covalently or non-covalently with the material from which the implant is prepared, generally a biologically inert polymer which is physiologically compatible. The implants are implanted in the tissue, and the drug is released such that the drug is substantially retained within the implant region. The device can be used to inhibit cellular proliferation around the implant. The device can be provided as a sterile kit, preferably in a form suitable for immediate use.
Inventors
- 👤 Peter Joseph Kelleher
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 10:49
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/28; A61K; A61K47/00; A61K47/50; A61K47/69; A61K47/6957; A61L27/50; A61L27/54; A61L31/00; A61L31/14; A61L31/16; A61L2300/00; A61L2300/40; A61L2300/416; A61L2300/60; A61L2300/602
Claims Analysis
Total Claims: 36
Claim 1
Independent Claim
88 words
An implant comprising: at least one agent which modulates proliferation of target cells, wherein said agent is bound to a polymer via a reactive group which mediates an interaction selected from the group consisting of: a hydrophobic interaction, a hydrophilic interaction, and a covalent interaction, wherein said interaction is labile under physiological conditions, so that said agent is released from said polymer when contacted with a tissue comprising said target cells without the use of an exogenously supplied releasing agent which changes the physiological conditions in said tissue.
Claim 2
Dependent Claim
88 words
An implant comprising: at least one agent which modulates proliferation of target cells, wherein said agent is bound to a polymer via a reactive group which mediates an interaction selected from the group consisting of: a hydrophobic interaction, a hydrophilic interaction, and a covalent interaction, wherein said interaction is labile under physiological conditions, so that said agent is released from said polymer when contacted with a tissue comprising said target cells without the use of an exogenously supplied releasing agent which changes the physiological conditions in said tissue.
Claim 3
Dependent Claim
30 words
The implant according to claim 1, wherein the rate at which said agent is released is controlled so as to restrict said agent to a localized region of said tissue.
Claim 4
Dependent Claim
29 words
The implant according to claim 1, wherein said rate is controlled by the molar substitution ratio of said agent to the number of said reactive groups on said polymer.
Claim 5
Dependent Claim
21 words
The implant of claim 1, wherein said reactive group is selected from the group consisting of carboxyl, amino, hydroxyl, and hydrazido.
Claim 6
Dependent Claim
11 words
The implant of claim 1, wherein said polymer comprises a polysaccharide.
Claim 7
Dependent Claim
15 words
The implant of claim 5, wherein said polysaccharide is hyaluronan or a salt of hyaluronan.
Claim 8
Dependent Claim
22 words
The implant of claim 1, wherein said polymer is selected from the group consisting of carboxymethylcellulose, polymethylmethacrylate, hydroxypropylmethylcellulose, hyaluronan, nylon, and silicone.
Claim 9
Dependent Claim
12 words
The implant of claim 1, wherein said agent inhibits target cell proliferation.
Claim 10
Dependent Claim
11 words
The implant of claim 8, wherein said agent comprises an antimitotic.
Claim 11
Dependent Claim
21 words
The implant of claim 9, wherein said antimitotic is selected from the group consisting of anthracycline, daunomycin, mitomycin C, and doxorubicin.
Claim 12
Dependent Claim
11 words
The implant of claim 8, wherein said agent comprises an antimetabolite.
Claim 13
Dependent Claim
10 words
The implant of claim 11, wherein said antimetabolite is 5-flourouracil.
Claim 14
Dependent Claim
11 words
The implant of claim 8, wherein said agent is a toxin.
Claim 15
Dependent Claim
10 words
The implant of claim 13, wherein said toxin is ricin.
Claim 16
Dependent Claim
12 words
The implant of claim 1, wherein said target cells are fibroblast cells.
Claim 17
Dependent Claim
12 words
The implant of claim 1, wherein said target cells are epithelial cells.
Claim 18
Dependent Claim
16 words
The implant of claim 1, wherein said agent and polymer are bound by a covalent bond.
Claim 19
Dependent Claim
13 words
The implant of claim 2, wherein said localized region is a filtration site.
Claim 20
Dependent Claim
15 words
The implant of claim 1, wherein said localized region is a lens capsule equatorial region.
Claim 21
Dependent Claim
19 words
The implant of claim 1, wherein said localized region is an abdominal surgery site or a pelvic surgery site.
Claim 22
Dependent Claim
124 words
An ocular implant comprising: at least one agent which modulates proliferation of target cells bound wherein said agent is bound to a polymer via a reactive group which mediates an interaction selected from the group consisting of: a hydrophobic interaction, a hydrophilic interaction, and a covalent interaction, wherein said interaction is labile under physiological conditions, so that said agent is released from said polymer when contacted with a tissue comprising said target cells without the use of an exogenously supplied releasing agent which changes the physiological conditions in said tissue, and wherein said agent is selected from the group consisting of daunomycin, mitomycin C, doxorubicin, and wherein said polymer is selected form the group consisting of hyaluronic acid, polymethylmethacrylate, hydroxypropylmethylcellulose, carboxymethylcellulose, silicone and nylon.
Claim 23
Dependent Claim
124 words
An ocular implant comprising: at least one agent which modulates proliferation of target cells bound wherein said agent is bound to a polymer via a reactive group which mediates an interaction selected from the group consisting of: a hydrophobic interaction, a hydrophilic interaction, and a covalent interaction, wherein said interaction is labile under physiological conditions, so that said agent is released from said polymer when contacted with a tissue comprising said target cells without the use of an exogenously supplied releasing agent which changes the physiological conditions in said tissue, and wherein said agent is selected from the group consisting of daunomycin, mitomycin C, doxorubicin, and wherein said polymer is selected form the group consisting of hyaluronic acid, polymethylmethacrylate, hydroxypropylmethylcellulose, carboxymethylcellulose, silicone and nylon.
Claim 24
Dependent Claim
10 words
The ocular implant of claim 21 which is a membrane.
Claim 25
Dependent Claim
29 words
The ocular implant of claim 21, wherein said implant is selected from the group consisting of an intraocular lens, a drainage shunt, a prosthesis, and a lens capsular loop.
Claim 26
Dependent Claim
13 words
The ocular implant according to claim 21 in a form suitable for injection.
Claim 27
Dependent Claim
33 words
A method for modulating proliferation of target cells in a localized region of the eye, said method comprising: contacting a localized region of the eye with an ocular implant according to claim 17.
Claim 28
Dependent Claim
16 words
The method of claim 25, wherein said localized region of the eye is a filtration site.
Claim 29
Dependent Claim
13 words
The method of claim 25, wherein said target cells are lens epithelial cells.
Claim 30
Dependent Claim
19 words
The method of claim 25, wherein said contacting is with an implant or through injection at a surgery site.
Claim 31
Dependent Claim
15 words
The method of claim 25, wherein said contacting is at the time of ocular surgery.
Claim 32
Dependent Claim
16 words
The method of claim 25, wherein said ocular surgery is cataract surgery or glaucoma filtering surgery.
Claim 33
Dependent Claim
25 words
A method of controlling formation of tissue adhesion sites, said method comprising: contacting tissue at a surgery site with an implant according to claim 1.
Claim 34
Independent Claim
130 words
A method of making a polymer implant comprising at least one agent which modulates proliferation of target cells bound wherein said agent is bound to a polymer via a reactive group which mediates an interaction selected from the group consisting of: a hydrophobic interaction, a hydrophilic interaction, and a covalent interaction, wherein said interaction is labile under physiological conditions, said method comprising: contacting a polymer having a sufficient number of reactive groups with a sufficient amount of an agent which modulates proliferation of target cells to form a bond which is labile under physiological conditions, so that said agent is released from said polymer when contacted with a tissue comprising said target cells without the use of an exogenously supplied releasing agent which changes the physiological conditions in said tissue.
Claim 35
Independent Claim
130 words
A method of making a polymer implant comprising at least one agent which modulates proliferation of target cells bound wherein said agent is bound to a polymer via a reactive group which mediates an interaction selected from the group consisting of: a hydrophobic interaction, a hydrophilic interaction, and a covalent interaction, wherein said interaction is labile under physiological conditions, said method comprising: contacting a polymer having a sufficient number of reactive groups with a sufficient amount of an agent which modulates proliferation of target cells to form a bond which is labile under physiological conditions, so that said agent is released from said polymer when contacted with a tissue comprising said target cells without the use of an exogenously supplied releasing agent which changes the physiological conditions in said tissue.
Claim 36
Dependent Claim
13 words
The implant of claim 17, wherein said covalent bond comprises a hydrazone linkage.
References Cited (Backward Citations)
US4093709A
Cited
US4937270A
Cited
US5098443A
Cited
US5578079A
Cited
US5080924A
Cited
EP0430539A2
Cited
WO1995003783A1
Cited
US5017229A
Cited
US5246698A
Cited
EP0488401A1
Cited
US5501856A
Cited
WO1995033492A1
Cited
US5618553A
Cited
US5554187A
Cited
US5728751A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2003-05-16 | 2003-11-15 | 2004-05-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2007-05-16 | 2007-11-15 | 2008-05-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2011-05-16 | 2011-11-15 | 2012-05-16 | $7700.00 | Window Closed / Lapsed |